Elite Pharmaceuticals, Inc.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Elite Pharmaceuticals, Inc. engages in the development and manufacture of pharmacological abuse-deterrent opioid products. It operates through the Abbreviated New Drug Applications (ANDA) and New Drug Applications (NDA) segments. The ANDA segment includes generic pharmaceuticals. The NDA segment is composed of branded pharmaceuticals. The company was founded on October 1, 1997 and is headquartered in Northvale, NJ.

Elite Pharmaceuticals, Inc. (ELTP) Q3 2024 Earnings Call Transcript

Conference Call Scheduled for Thursday, February 15 at 11:30 AM EST NORTHVALE, NJ / ACCESSWIRE / February 14, 2024 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company")(OTCBB:ELTP), a specialty pharmaceutical company engaged in the development, manufacture, and distribution of niche generic products, announced results for the third quarter of fiscal year 2024 ended December 31, 2023 ("Third Quarter"). Consolidated revenues for the three-month period ended December 31, 2023, were $15.5 million, an increase of $6.3 million or 68% as compared to the comparable period of the prior fiscal year.

Elite Pharmaceuticals, Inc. Reports Financial Results for Third Quarter of Fiscal Year 2024 ended December 31, 2023 and Provides Conference Call Information

Financials for Third Quarter Fiscal Year 2024 Ended December 31, 2023 will be released on February 14, 2024 NORTHVALE, NJ / ACCESSWIRE / February 8, 2024 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing niche generic products, announced today that the third quarter financial results of the 2024 fiscal year will be released on Wednesday, February 14, 2024. Elite's management will host a live conference call on Thursday, February 15th, at 11:30 AM EST to discuss the company's financial and operating results and provide a general business update.

Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2024 Financial Results on February 15, 2024

NORTHVALE, NJ / ACCESSWIRE / December 26, 2023 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP), a specialty pharmaceutical company engaged in the development, manufacture, and distribution of niche generic products, today announced the US Food and Drug Administration's (FDA) acceptance for review of an Abbreviated New Drug Application (ANDA) on December 21, 2023, for an undisclosed generic drug product in a class of medications known as central nervous stimulants. IQVIA reported annual sales for the twelve months ending June 2023 of $5.1 billion for the brand and generic market for this product.

Elite Pharmaceuticals Files ANDA with US FDA to Market Central Nervous System Stimulant

NORTHVALE, NJ / ACCESSWIRE / December 12, 2023 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing niche generic products, today announced the first shipment of generic Adderall XR® to its distribution and marketing partner Prasco, LLC ("Prasco"). Adderall XR® is an extended-release mixed salt of a single entity Amphetamine product (Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate) with strengths of 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, and 30 mg capsules (the "Products").

Elite Pharmaceuticals Announces First Product Shipment of Generic Adderall XR(R) to Marketing Partner Prasco, LLC

Broadwind Energy

Overseas Shipholding Group

Pitney Bowes

Ammo

CarParts.com, Inc.

Redwire Corp

The equities market can feel like navigating through a fog while searching for the best penny stocks. Yet, amidst this uncertainty, a handful of names emerge as clear winners, displaying robust resilience and performance throughout the year.

Small Stocks, Big Potential: 7 Penny Stocks Poised for Major Gains in 2024

Elite Pharmaceuticals, Inc. (OTCQB:ELTP) Q2 2024 Earnings Call Transcript November 15, 2023 11:30 AM ET Company Participants Nasrat Hakim - President and Chief Executive Officer Carter Ward - Chief Financial Officer Conference Call Participants Operator Good morning, ladies and gentlemen, and welcome to Elite Pharmaceuticals Conference Call. At this time all lines have been placed on a listen-only moder.

Elite Pharmaceuticals, Inc. (ELTP) Q2 2024 Earnings Call Transcript

Conference Call Scheduled for Wednesday, November 15 at 11:30 AM EST NORTHVALE, NJ / ACCESSWIRE / November 14, 2023 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company engaged in the development, manufacture, and distribution of niche generic products, announced results for the second quarter of fiscal year 2024 ended September 30, 2023 ("Second Quarter"). Consolidated revenues for the three-month period ended September 30, 2023, were $14.2 million, an increase of $5.6 million or 64.9% as compared to the comparable period of the prior fiscal year.

Elite Pharmaceuticals, Inc. Reports Financial Results for Second Quarter of Fiscal Year 2024 ended September 30, 2023 and Provides Conference Call Information

Financials for Second Quarter Fiscal Year 2024 Ended September 30, 2023 will be released on November 14, 2023 NORTHVALE, NJ / ACCESSWIRE / November 10, 2023 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP), a specialty pharmaceutical company developing niche generic products, announced today that the second quarter financial results of the 2024 fiscal year will be released on Tuesday, November 14, 2023. Elite's management will host a live conference call on Wednesday, November 15th, at 11:30 AM EST to discuss the company's financial and operating results and provide a general business update.

Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2024 Financial Results on November 15, 2023

Bitfarms Ltd

Clearsign Combustion

Terran Orbital Corp

Polestar Automotive Holding UK PLC

Navigating the stock market's murky waters, the forecast for promising penny stocks might seem overcast. Within this realm, though, certain names are bucking the trend, boasting robust performances throughout the year.

7 Penny Stocks With Promising Potential Catalysts in 2024

Mama's Creations Inc

PCTEL

PHX Minerals

When it comes to stock predictions and penny stocks to buy, admittedly the near-term picture remains cloudy. Right now, it's unclear whether high interest rates, high inflation, and the still-present risk of a 2024 recession are fully priced-in by the stock market.

Q4 Stock Predictions: 7 Penny Stocks Ready to Roar Into 2024

NORTHVALE, NJ / ACCESSWIRE / September 25, 2023 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company")(OTCQB:ELTP), a specialty pharmaceutical company engaged in the development, manufacture, and distribution of niche generic products, today announced that it filed an Abbreviated New Drug Application (ANDA) on August 17, 2023, and was accepted for review by the US Food and Drug Administration (FDA) on September 19, 2023 for an undisclosed generic drug product in a class of medications called opiate analgesics. IQVIA reported annual sales for the twelve months ending June 2023 of $720 million for the brand and generic market for this product.

Elite Pharmaceuticals Files ANDA with US FDA to Market Opiate Analgesic Product

NORTHVALE, NJ / ACCESSWIRE / September 7, 2023 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing and manufacturing niche generic products, today announced the appointment of Carter Ward as its Chief Financial Officer (CFO), effective September 5, 2023. Mr. Ward previously served as the Company's Chief Financial Officer from July 2009 through May 2021, and the Company is pleased to have Mr.

Elite Pharmaceuticals, Inc. Appoints Carter Ward as Chief Financial Officer

Flexible Solutions

OppFi

Optex Systems Holdings Inc

Profire Energy

“Penny stock territory” may be chock full of “fallen angels,” former high-fliers, along with shares in companies with minimal growth prospects, but among the thousands of publicly-traded stocks, there are quite a few up-and-coming penny stocks as well. Although investors in recent years have been burned by low-priced ($5 per share or less) speculative growth plays that failed to live up to expectations, there are names in this category that have reported both revenue and earnings growth in recent years.

7 Up-and-Coming Penny Stocks to Put on Your Must-Buy List

NORTHVALE, NJ / ACCESSWIRE / August 28, 2023 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company")(OTCQB:ELTP), a specialty pharmaceutical company engaged in the development, manufacture, and distribution of niche generic products, today reported positive results from pivotal fed and fasted bioequivalence studies for an undisclosed generic drug product in a class of medications called CNS stimulants. IQVIA reported annual sales for the twelve months ending June 2023 of $5.1 billion for the brand and generic market for this product.

Elite Pharmaceuticals Reports Positive Results from a Pivotal Bioequivalence Study

Elite Pharmaceuticals, Inc. (OTCQB:ELTP) Q1 2024 Results Conference Call August 15, 2023 11:30 AM ET Company Participants Nasrat Hakim - President and Chief Executive Officer Operator Good morning, ladies and gentlemen, and welcome to the Elite Pharmaceuticals First Quarter of Fiscal Year 2024 Conference Call. At this time, all lines have been placed on a listen-only mode.

Elite Pharmaceuticals, Inc. (ELTP) Q1 2024 Earnings Call Transcript

Financials for First Quarter Fiscal Year 2024 Ended June 30, 2023 will be released on August 14, 2023 NORTHVALE, NJ / ACCESSWIRE / August 9, 2023 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing niche generic products, announced today that the first quarter financial results of the 2024 fiscal year will be released on Monday, August 14, 2023. Elite's management will host a live conference call on Tuesday, August 15th, at 11:30 AM EDT to discuss the company's financial and operating results and provide a general business update.

Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss First Quarter 2024 Financial Results on August 15, 2023

Elite Pharmaceuticals, Inc. (OTCQB:ELTP) Q4 2023 Earnings Conference Call June 30, 2023 11:30 AM ET Company Participants Nasrat Hakim - President and Chief Executive Officer Conference Call Participants Operator Good morning, ladies and gentlemen, and welcome to the Elite Pharmaceuticals Conference Call. At this time, all lines have been placed on a listen-only mode.

Elite Pharmaceuticals, Inc. (ELTP) Q4 2023 Earnings Call Transcript

Conference Call Scheduled for Friday, June 30 at 11:30 AM EDT NORTHVALE, NJ / ACCESSWIRE / June 29, 2023 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing niche generic products, announced results for the fiscal year ended March 31, 2023 ("Fiscal 2023"). Consolidated revenues for Fiscal 2023 were $34.2 million, an increase of $1.9 million or 5.9% as compared to the comparable period of the prior fiscal year.

Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2023 and Provides Conference Call Information

Financials for Fiscal Year 2023 Ended March 31, 2023 will be released on June 29, 2023 NORTHVALE, NJ / ACCESSWIRE / June 22, 2023 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing niche generic products, announced today that it would release its 2023 year-end financial results on Thursday, June 29, 2023. Elite's management will host a live conference call Friday, June 30th at 11:30 AM EDT to discuss the company's financial and operating results and provide a general business update.

Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Fiscal Year 2023 Financial Results on June 30, 2023

Butler National Corporation

Whether you're a growth investor, a value investor, or something in-between, the over-the-counter (or OTC) market is a great place to look for opportunities. Even though many carry higher risk, there are scores of OTC stocks with high potential.

7 OTC Stocks to Buy With Boatloads of Potential

NORTHVALE, NJ / ACCESSWIRE / May 3, 2023 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing and manufacturing niche generic products, today announced the appointment of Mark Pellegrino as its Chief Financial Officer (CFO), effective May 1, 2023. Pellegrino joins Elite with more than 30 years of experience in financial and operational leadership, primarily in the life sciences sector, including manufacturing and distribution.

Elite Pharmaceuticals, Inc. Appoints Mark Pellegrino as Chief Financial Officer

NORTHVALE, NJ / ACCESSWIRE / April 20, 2023 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP), a specialty pharmaceutical company developing niche generic products, today announced that it filed an Abbreviated New Drug Application (ANDA) with the US Food and Drug Administration (FDA) for an undisclosed generic drug product in a class of medications called antimetabolites. IQVIA reported annual sales for the twelve months ending December 2022 of $42 million for the generic market for this product.

Elite Pharmaceuticals Files ANDA with US FDA to Market Antimetabolite Product

Elite Pharmaceuticals, Inc. (OTCQB:ELTP) Q3 2023 Earnings Conference Call February 15, 2023 11:30 AM ET Company Participants Nasrat Hakim - President and Chief Executive Officer Robert Chen - Chief Financial Officer Conference Call Participants Operator Good morning, ladies and gentlemen, and welcome to the Elite Pharmaceuticals Conference Call. At this time, all lines have been placed on a listen-only mode.

Elite Pharmaceuticals, Inc. (ELTP) Q3 2023 Earnings Call Transcript

Conference Call Scheduled for Wednesday, February 15 at 11:30 AM EST NORTHVALE, NJ / ACCESSWIRE / February 14, 2023 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing niche generic products, announced results for the third quarter of fiscal year 2023 ended December 31, 2022 ("Third Quarter"). Consolidated revenues for the three-month period ended December 31, 2022, were $9.3 million, an increase of $0.30 million or 3% as compared to the comparable period of the prior fiscal year.

Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2023 ended December 31, 2022 and Provides Conference Call Information

News for Elite Pharmaceuticals, Inc. Stock (ELTP)